文献速递艾滋病与性传播感染新发突发、热带与寄生虫病

HIV感染者连续接种新冠疫苗加强针后的体液与细胞免疫应答

Humoral and cellular immune responses in people living with HIV following successive COVID-19 vaccine booster doses.
PubMed 文献 · Clin Microbiol Infect · 2025-06-11

该前瞻性研究随访151例接受抑制性抗逆转录病毒治疗的HIV感染者,评估连续接种两剂新冠疫苗加强针后针对 Ancestral、Delta 和 Omicron 变异株的抗体、记忆B细胞和T细胞应答。结果显示加强针逐步增强免疫应答,但CD4≤350 cells/mm3者记忆B细胞产生受损,且未感染过新冠病毒的质粒载体疫苗接种者抗体水平较低、突破感染率较高。

要点

  • 连续加强接种可逐步提升HIV感染者的抗体、记忆B细胞和T细胞应答。
  • CD4≤350 cells/mm3者第三剂后记忆B细胞比例低于CD4>500者。
  • 未感染过新冠病毒的质粒载体疫苗接种者抗体较低且突破感染率较高。

核心结论

  • 连续接种新冠疫苗加强针可显著增强HIV感染者的体液和细胞免疫应答,降低重症感染风险并可能减少新发感染。
  • 低CD4计数导致记忆B细胞产生减少,需定制化接种策略;mRNA疫苗在变异株流行期间对突破感染提供更优保护。

研究设计与样本

  • 前瞻性研究随访151例接受抑制性抗逆转录病毒治疗且已完成初始新冠疫苗接种并接种两剂额外疫苗的HIV感染者。
  • 评估SARS-CoV-2特异性抗体、SARS-CoV-2-ACE2结合抑制率、刺突特异性记忆B细胞及CD4/CD8细胞对Ancestral、Delta和Omicron变异株的应答,并考虑初始疫苗类型、既往感染和免疫抑制水平。

主要发现

  • 疫苗剂量逐步增强抗体水平、记忆B细胞和T细胞应答,且免疫应答在各变异株间保持一致。
  • CD4≤350 cells/mm3者第三剂后记忆B细胞产生低于CD4>500 cells/mm3者(0.39% [0.29-0.55] vs. 0.68% [0.49-0.86];p < 0.001)。
  • 未感染过新冠病毒的质粒载体疫苗接种者针对Delta和Omicron的抗体水平低于感染过新冠病毒者(Delta:10 930 ng/mL [9623-12 511] vs. 13 340 ng/mL [10 602-14 724],p 0.018;Omicron:399 ng/mL [335-702] vs. 615 ng/mL [492-924],p 0.041)。
  • 第三剂加强后IgA产生记忆B细胞增加,尤其在mRNA疫苗中(未感染个体:0.05% [0.0-0.09] vs. 0.11 [0.07-0.17],p < 0.001)。
  • 加强后感染率在既往未感染者中更高(第二剂加强后25% vs. 4%,p < 0.001),尤其在载体疫苗接种者中(34.6% vs. 14.5%,p 0.028)。

临床怎么用

  • 对CD4计数较低的HIV感染者应考虑定制化加强接种策略以改善记忆B细胞应答。
  • 在变异株流行期间,mRNA疫苗可能为HIV感染者提供更优的突破感染保护。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to evaluate humoral and cellular immune responses in people living with HIV (PLWH) following successive COVID-19 vaccine booster doses, to determine immune correlates associated with clinical outcomes (avoiding severe infections) and epidemiological impacts (preventing new infections), a topic of growing controversy in this vulnerable population. METHODS: A prospective study followed 151 PLWH on suppressive antiretroviral therapy who completed initial COVID-19 vaccination and received two additional vaccine doses. The study evaluated changes in SARS-CoV-2-specific antibodies, SARS-CoV-2-ACE2 binding inhibition rates, spike-specific memory B cells, and CD4/CD8 cell responses to variants (Ancestral, Delta, and Omicron), considering initial vaccine type, prior infections, and levels of immunosuppression. RESULTS: Vaccine doses progressively enhanced antibody levels, memory B cells, and T-cell responses. PLWH with CD4 counts ≤350 cells/mm3 showed impaired memory B cell production vs. those with CD4 >500 cells/mm3 after the third dose (0.39% [0.29-0.55] vs. 0.68% [0.49-0.86]; p < 0.001). Immune responses remained consistent across variants. Non-infected PLWH receiving plasmid vector vaccines demonstrated lower antibody levels against Delta and Omicron (10 930 ng/mL [9623-12 511] vs. 13 340 ng/mL [10 602-14 724], p 0.018; 399 ng/mL [335-702] vs. 615 ng/mL [492-924], p 0.041) compared with infected PLWH. IgA-producing memory B cells increased after the third booster, particularly with mRNA vaccines (0.05% [0.0-0.09] vs. 0.11 [0.07-0.17], p < 0.001 in non-infected individuals). Post-booster infection rates were higher in previously uninfected individuals (25% vs. 4% after the second booster, p < 0.001), especially among vector vaccine recipients (34.6% vs. 14.5%, p 0.028). DISCUSSION: This study reveals that successive vaccine doses significantly enhance immune responses in PLWH, improving antibody levels, IgA+ memory B cells, and T-cell responses, thereby reducing the risk of severe infections and potentially new infections. Nevertheless, low CD4 counts result in reduced memory B cells, necessitating tailored vaccination strategies. mRNA vaccines also offer superior protection against breakthrough infections during variant surges.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Casado JL, Vizcarra P, Martín-Hondarza A, et al. Humoral and cellular immune responses in people living with HIV following successive COVID-19 vaccine booster doses. Clin Microbiol Infect. 2025. PMID: 40513829. doi:10.1016/j.cmi.2025.06.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。